Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 1
2006 2
2008 1
2009 1
2011 2
2012 4
2013 3
2014 5
2015 5
2016 3
2017 4
2018 1
2019 2
2020 4
2021 4
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice.
Inomata M, Tsuda T, Ichikawa T, Matsumoto M, Mizushima I, Azechi K, Takata N, Murayama N, Hayashi K, Hirai T, Seto Z, Tokui K, Masaki Y, Taka C, Okazawa S, Kambara K, Imanishi S, Taniguchi H, Miwa T, Hayashi R, Matsui S, Tobe K. Inomata M, et al. Among authors: okazawa s. Thorac Cancer. 2023 Jun;14(17):1618-1623. doi: 10.1111/1759-7714.14907. Epub 2023 Apr 26. Thorac Cancer. 2023. PMID: 37101081 Free PMC article.
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Inomata M, Matsumoto M, Mizushima I, Seto Z, Hayashi K, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K. Inomata M, et al. Among authors: okazawa s. Cancer Diagn Progn. 2022 May 3;2(3):324-329. doi: 10.21873/cdp.10112. eCollection 2022 May-Jun. Cancer Diagn Progn. 2022. PMID: 35530643 Free PMC article.
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Inomata M, Matsumoto M, Hayashi K, Seto Z, Hirai T, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K. Inomata M, et al. Among authors: okazawa s. Anticancer Res. 2023 Jul;43(7):3241-3246. doi: 10.21873/anticanres.16498. Anticancer Res. 2023. PMID: 37351972
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancer.
Tsuda T, Suzuki K, Inomata M, Hayashi K, Mizushima I, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Masaki Y, Taniguchi H, Tobe K. Tsuda T, et al. Among authors: okazawa s. Mol Clin Oncol. 2023 Mar 17;18(5):38. doi: 10.3892/mco.2023.2634. eCollection 2023 May. Mol Clin Oncol. 2023. PMID: 37035471 Free PMC article.
45 results